Mainz
Mainz, DE-55101, Germany
NCT Number: NCT00519753
The purpose of this study is to assess the safety and efficacy of transitioning uncontrolled glaucoma patients to DuoTrav from other mono or adjunctive therapies.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Mainz, DE-55101, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
Other names: DUOTRAV®
Time frame: Baseline and 12 weeks
Time frame: 12 weeks
Alcon Research
Industry
Safety and Efficacy of Switching to the Travoprost/Timolol Maleate Fixed Combination (DUOTRAV®) From Prior Mono or Two-Drug Therapy in Germany
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07592988
Eye Diseases, Glaucoma
Almaty, Kazakhstan
View Trial DetailsNCT07592923
Eye Diseases, Glaucoma
Almaty, Kazakhstan
View Trial DetailsNCT03076697
Age Related Macular Degeneration, Cardiovascular Diseases
View Trial DetailsNCT07763288
Blind Eye, Blindness
Nonthaburi, Thailand
View Trial Details